Nuveen’s Acumen Pharmaceuticals ABOS Stock Holding History

Nuveen’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-78,446	Closed	-$86.3K	–	3274
2025 Q1	$86.3K	Hold	78,446	–	–	﹤0.01%	3227
2024 Q4	$135K	Hold	78,446	–	–	﹤0.01%	3265
2024 Q3	$195K	Buy	78,446 +21,782	+38%	+$59.1K	﹤0.01%	3228
2024 Q2	$137K	Buy	+56,664	New	+$180K	﹤0.01%	3283
2022 Q2	–	Sell	-39,241	Closed	-$235K	–	3224
2022 Q1	$235K	Buy	39,241 +26,319	+204%	+$143K	﹤0.01%	3160
2021 Q4	$81K	Hold	12,922	–	–	﹤0.01%	3291
2021 Q3	$192K	Buy	+12,922	New	+$215K	﹤0.01%	3280

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Nuveen's ABOS Position: Q2 2025 in Review

Nuveen sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 78,446 shares — an estimated $86.3K sold.

Nuveen first reported a position in ABOS in Q3 2021 and held it in 7 quarters. The position peaked at $235K in Q1 2022. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

Nuveen reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Nuveen sold 78,446 Acumen Pharmaceuticals shares in Q2 2025, an estimated $86.3K.
Nuveen first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Nuveen's Acumen Pharmaceuticals position peaked at $235K in Q1 2022.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.